StockNews.AI
AWH
StockNews.AI
145 days

Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results

1. Aspira Women's Health reported $9.2 million OvaSuite revenue for 2024. 2. Fourth quarter 2024 product revenue rose 9.5% year-over-year.

Earnings
-4.36%Current Return
VS
-2%S&P 500
$0.1103/27 04:08 PM EDTEvent Start
$0.105203/28 10:21 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The increase in revenue indicates strong operational performance, which could enhance investor confidence. Historical data shows that consistent revenue growth often leads to positive stock movements.

How important is it?

Revenue growth is critical for AWH. Positive earnings can attract institutional investment and boost share price.

Why Short Term?

Immediate investor reactions are likely following positive revenue announcements, especially quarterly results. However, sustained growth will depend on future performance.

Related Companies

AWH
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent Financial Highlights • Product revenue increased 9.5% to $2.3 million for the three months ended December 31, 2024, compared to $2.1 million for the same period in 2023.

Related News